Clinical Trials Logo

Clinical Trial Summary

This study aimed to evaluate the effect of a vegan diet (supplemented with vitamin B12) and an mediterranean diet on performance, cardiorespiratory fitness, metabolic health, immune status, and environmental impact in healthy adults.


Clinical Trial Description

OMNIVEG is a controlled crossover trial. Initially, registered dietitians conducted an assessment of participants' lifestyles in a preliminary session. Qualified nutritionists then developed personalized diets for each participant in accordance with the recommendations of the International Society of Sports Nutrition (ISSN). These diets followed specific guidelines, including a daily intake of 3-5 g of carbohydrates per kilogram of body weight, 1.4-2.0 g of protein per kilogram of body weight, and 0.5-1.5 g of fat per kilogram of body weight. Both the mediterranean diet and vegan diets prescribed to the participants were isocaloric, with similar distributions of macronutrients. The primary difference between the two interventions was the source of food: the vegan diet exclusively comprised plant-based foods, while the omnivorous diet included foods of both animal and plant sources. In the case of the omnivorous diet, 60% of the total protein intake was derived from animal sources (mainly from fish, white meat, low-fat dairy and eggs). As part of the vegan diet, participants were instructed to take 1000 µg of cyanocobalamin (a form of vitamin B12) twice a week from Harrison Sport Nutrition, Granada, Spain. This supplementation aimed to ensure adequate vitamin B12 intake, which is essential for individuals following a vegan diet. Throughout the study period, participants were advised to maintain their initial physical exercise frequency and volume to maintain consistency and avoid confounding variables. To ensure standardized measurements, all tests were conducted in the same laboratory, employing identical testing devices, and supervised by the same group of researchers. This approach aimed to minimize experimental variability and improve the reliability of the study's results. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06008886
Study type Interventional
Source Universidad Francisco de Vitoria
Contact
Status Completed
Phase N/A
Start date June 19, 2023
Completion date September 4, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05880758 - Impact of Yo-Yo Sleep on Cardiometabolic Health N/A
Active, not recruiting NCT05192590 - Establishing Clinical Utility Evidence for Chronic Disease Management Testing N/A
Completed NCT06058845 - Efficacy of Tamarindus Indica Fruit Juice in Optimizing Cardiometabolic Health of Patients Living With HIV N/A
Completed NCT05473026 - Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors N/A
Enrolling by invitation NCT06284772 - FINRISK 2002 Re-examination
Completed NCT05071833 - Effects of Peppermint Oil in Cardiometabolic Outcomes N/A
Active, not recruiting NCT05309057 - Network Meta-analysis of Intermittent Fasting and Cardiometabolic Risk
Recruiting NCT05897073 - Time-Restricted Eating, Exercise and Cardiometabolic Health in Obesity N/A
Recruiting NCT06371937 - iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease
Recruiting NCT06003686 - Spinal Cord Injury Model Systems (SCIMS) - Education Module N/A
Recruiting NCT05775016 - Effects of Adding L-BAIBA to Exercising Adult Overweight and Obese Men and Women N/A
Recruiting NCT05350111 - CArdioMetabolic Prevention in Adolescents N/A
Completed NCT06158191 - Long-term Benefits of Abdominal Fat Loss in Abdominally Obese Dyslipidemic Patients (SYNERGIE Study) N/A
Recruiting NCT04801745 - Vegan Diet, Amla Fruits and Uric Acid N/A
Not yet recruiting NCT06230861 - Effects of Quercetin on Cardiometabolic Outcomes N/A
Active, not recruiting NCT05627570 - A Study Comparing the Health Effects of Two Diets Following UK Dietary Guidance in People Living With Overweight or Obesity N/A
Active, not recruiting NCT04784624 - Virtual Lifestyle Program Evaluation During Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Enrolling by invitation NCT05079529 - Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome Phase 2
Completed NCT04776629 - A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors Phase 2
Completed NCT06457711 - Blood Pressure and Cardiometabolic Risk (Diet-to-HTN) N/A